الفهرس 
Title : A pharmaceutical study on mosapride for intranasal administration
ContantsOnly 14 pages are availabe for public view
 |  | from | 312 |  |  |
| | | from | 312 | | |
Abstract
Mosapride citrate (MOS) is a potent gastroprokinetic agent, used in the treatment of various gastrointestinal disorders caused by reduced gastrointestinal motility including gastroesophageal reflux disease (GERD). MOS would neither result in cardiac nor nervous adverse reactions due to selective stimulation of serotonin 5-HT4 receptors, without any considerable affinity for dopamine D2, 5-HT1, 5-HT2, or adrenergic receptors. Presently, available tablet dosage formulation of MOS is incapable to achieve the required clinical efficacy. Its short half-life (t1/2), intensive first-pass metabolism, poor solubility, and poor wettability lower its oral bioavailability to be 8-14%.This very low oral bioavailability restricts its use. So, the aim of this study was to improve the bioavailability MOS through intranasal administration